RU2002129298A - Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера - Google Patents
Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера Download PDFInfo
- Publication number
- RU2002129298A RU2002129298A RU2002129298/14A RU2002129298A RU2002129298A RU 2002129298 A RU2002129298 A RU 2002129298A RU 2002129298/14 A RU2002129298/14 A RU 2002129298/14A RU 2002129298 A RU2002129298 A RU 2002129298A RU 2002129298 A RU2002129298 A RU 2002129298A
- Authority
- RU
- Russia
- Prior art keywords
- dose
- day
- galantamine
- administered
- use according
- Prior art date
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title claims 24
- 229960003980 galantamine Drugs 0.000 title claims 12
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title claims 12
- 208000024827 Alzheimer disease Diseases 0.000 title claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19425900P | 2000-04-03 | 2000-04-03 | |
| US60/194,259 | 2000-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2002129298A true RU2002129298A (ru) | 2004-03-27 |
Family
ID=22716898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002129298/14A RU2002129298A (ru) | 2000-04-03 | 2001-03-28 | Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1272192A2 (fr) |
| JP (1) | JP2003528913A (fr) |
| KR (1) | KR20020086911A (fr) |
| CN (1) | CN1430514A (fr) |
| AU (2) | AU6584401A (fr) |
| BG (1) | BG107093A (fr) |
| BR (1) | BR0109770A (fr) |
| CA (1) | CA2310926C (fr) |
| CZ (1) | CZ20023543A3 (fr) |
| EE (1) | EE200200554A (fr) |
| HR (1) | HRP20020778A2 (fr) |
| HU (1) | HUP0300566A3 (fr) |
| IL (1) | IL152061A0 (fr) |
| MX (1) | MXPA02009777A (fr) |
| NO (1) | NO20024746L (fr) |
| PL (1) | PL361272A1 (fr) |
| RU (1) | RU2002129298A (fr) |
| SK (1) | SK15422002A3 (fr) |
| WO (1) | WO2001074339A2 (fr) |
| ZA (1) | ZA200207935B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
| ATE374030T1 (de) * | 2003-07-25 | 2007-10-15 | Hoffmann La Roche | Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| DK2271218T3 (en) | 2008-03-27 | 2017-09-11 | Chase Pharmaceuticals Corp | USE AND COMPOSITION TO TREAT DEMENS |
| WO2013160728A1 (fr) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Composés à double ciblage pour le traitement de la maladie d'alzheimer |
| BG66818B1 (bg) * | 2013-03-07 | 2019-01-31 | Berbee Beheer B. V. | Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки |
| WO2016187339A1 (fr) * | 2015-05-18 | 2016-11-24 | Synaptec Development Llc | Clairance de galantamine d'amyloides |
| WO2023036105A1 (fr) * | 2021-09-09 | 2023-03-16 | 上海日馨医药科技股份有限公司 | Méthode de traitement d'une maladie neurodégénérative |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| GB9600080D0 (en) * | 1996-01-04 | 1996-03-06 | Chiroscience Ltd | Resolution process |
| EP1133230A4 (fr) | 1998-11-23 | 2004-05-26 | Bonnie M Davis | Formulations de dosage d'inhibiteurs de l'acetylcholinesterase |
| ID29021A (id) * | 1998-12-24 | 2001-07-26 | Janssen Pharmaceutica Nv | Komposisi galantamina pelepasan terkontrol |
| CA2310950C (fr) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | Posologie de galantamine efficace qui reduit les effets secondaires |
| CA2310990A1 (fr) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | Utilisation de la galantamine pour le traitement de la maladie d'alzheimer; ciblage de la cause sous-jacente de la maladie |
-
2000
- 2000-06-27 CA CA002310926A patent/CA2310926C/fr not_active Expired - Lifetime
-
2001
- 2001-03-28 MX MXPA02009777A patent/MXPA02009777A/es unknown
- 2001-03-28 EP EP01943200A patent/EP1272192A2/fr not_active Withdrawn
- 2001-03-28 HU HU0300566A patent/HUP0300566A3/hu unknown
- 2001-03-28 JP JP2001572084A patent/JP2003528913A/ja not_active Withdrawn
- 2001-03-28 EE EEP200200554A patent/EE200200554A/xx unknown
- 2001-03-28 AU AU6584401A patent/AU6584401A/xx active Pending
- 2001-03-28 CN CN01807334A patent/CN1430514A/zh active Pending
- 2001-03-28 IL IL15206101A patent/IL152061A0/xx unknown
- 2001-03-28 CZ CZ20023543A patent/CZ20023543A3/cs unknown
- 2001-03-28 AU AU2001265844A patent/AU2001265844B2/en not_active Ceased
- 2001-03-28 SK SK1542-2002A patent/SK15422002A3/sk unknown
- 2001-03-28 HR HR20020778A patent/HRP20020778A2/xx not_active Application Discontinuation
- 2001-03-28 WO PCT/EP2001/003553 patent/WO2001074339A2/fr not_active Ceased
- 2001-03-28 PL PL36127201A patent/PL361272A1/xx not_active Application Discontinuation
- 2001-03-28 BR BR0109770-9A patent/BR0109770A/pt not_active IP Right Cessation
- 2001-03-28 RU RU2002129298/14A patent/RU2002129298A/ru not_active Application Discontinuation
- 2001-03-28 KR KR1020027011063A patent/KR20020086911A/ko not_active Ceased
-
2002
- 2002-09-12 BG BG107093A patent/BG107093A/bg unknown
- 2002-10-02 ZA ZA200207935A patent/ZA200207935B/en unknown
- 2002-10-02 NO NO20024746A patent/NO20024746L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0300566A2 (hu) | 2003-06-28 |
| BR0109770A (pt) | 2003-02-04 |
| EE200200554A (et) | 2004-04-15 |
| BG107093A (bg) | 2003-06-30 |
| NO20024746D0 (no) | 2002-10-02 |
| CN1430514A (zh) | 2003-07-16 |
| KR20020086911A (ko) | 2002-11-20 |
| AU6584401A (en) | 2001-10-15 |
| HUP0300566A3 (en) | 2004-10-28 |
| MXPA02009777A (es) | 2003-03-27 |
| ZA200207935B (en) | 2004-01-30 |
| SK15422002A3 (sk) | 2003-04-01 |
| CA2310926C (fr) | 2002-10-15 |
| EP1272192A2 (fr) | 2003-01-08 |
| NO20024746L (no) | 2002-11-28 |
| HRP20020778A2 (en) | 2004-04-30 |
| WO2001074339A2 (fr) | 2001-10-11 |
| CA2310926A1 (fr) | 2000-10-04 |
| CZ20023543A3 (cs) | 2003-03-12 |
| JP2003528913A (ja) | 2003-09-30 |
| PL361272A1 (en) | 2004-10-04 |
| IL152061A0 (en) | 2003-05-29 |
| AU2001265844B2 (en) | 2005-04-14 |
| WO2001074339A3 (fr) | 2002-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005065069A3 (fr) | Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer | |
| ES2089027T3 (es) | Forma de dosificacion transmucosica. | |
| RU2008116931A (ru) | Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей | |
| JP2005515966A5 (fr) | ||
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| RU2002121546A (ru) | Вещества, предназначенные для лечения псориаза | |
| JP2004537500A5 (fr) | ||
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| EP1372682A4 (fr) | Catechines destinees au traitement de la fibrillogenese dans la maladie d'alzheimer, la maladie de parkinson, l'amylose aa systemique, et autres troubles amyloides | |
| RU2002129298A (ru) | Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера | |
| JP2002544233A5 (fr) | ||
| JP2003514025A5 (fr) | ||
| JP2002540148A5 (fr) | ||
| RU2003127718A (ru) | Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости | |
| JP2003523385A5 (fr) | ||
| CA2368352A1 (fr) | Procede de traitement de la neuro degenerescence | |
| RU2003100081A (ru) | Способы и композиции, в которых используется сулодексид, для лечения диабетической нефропатии | |
| RU95112520A (ru) | Применение 4'-йодо-4'-деоксидоксорубицина для лечения амилоидоза, способ лечения амилоидоза | |
| RU2006110550A (ru) | Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна | |
| JPH10175852A5 (fr) | ||
| EA200300430A1 (ru) | Новые фармацевтические композиции, содержащие эпинастин и псевдоэфедрин | |
| AR020167A1 (es) | Metodo para la prevencion del inicio del asma | |
| JPH10175860A5 (fr) | ||
| RU94023600A (ru) | Способ лечения гемохроматоза | |
| RU2001128509A (ru) | Способ лечения нейродегенерации |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20060405 |